A Phase 3 interventional study of F/TAF and ABC/3TC in HIV-1 Infection, sponsored by Gilead Sciences. Completed at 80 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-25.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of switching abacavir/lamivudine (ABC/3TC) fixed-dose combination (FDC) tablets to emtricitabine/tenofovir alafenamide (F/TAF) FDC tablets versus maintaining ABC/3TC in human immunodeficiency virus type 1 (HIV-1) infected adults who are virologically suppressed on regimens containing ABC/3TC.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
F/TAF + ABC/3TC placebo + allowed 3rd antiretroviral (ARV) agent for 96 weeks After Week 96, participants will continue to take their blinded study drug and attend visits every 12 weeks until treatment assignments have been unblinded.
Drug: F/TAF · Drug: ABC/3TC Placebo · Drug: 3rd ARV agent
ABC/3TC + F/TAF placebo + allowed 3rd ARV agent for 96 weeks After Week 96, participants will continue to take their blinded study drug and attend visits every 12 weeks until treatment assignments have been unblinded.
Drug: ABC/3TC · Drug: F/TAF Placebo · Drug: 3rd ARV agent
After the unblinding visit, in countries where F/TAF FDC is not commercially available, participants (except in certain countries such as the UK) will be given the option to receive open-label F/TAF (200/10 mg or 200/25 mg) FDC and attend study visits every 12 weeks until it becomes commercially available, or until Gilead terminates the study in that country.
Drug: F/TAF
Drug pages: Emtricitabine · Tenofovir alafenamide
200/10 mg FDC tablet (with boosted 3rd ARV agents) or 200/25 mg FDC tablet (with unboosted 3rd ARV agents) administered orally once daily
Also known as: Descovy®
600/300 mg FDC tablets administered orally once daily
Tablets administered orally once daily
Tablets administered orally once daily
An allowed 3rd ARV agent of the participant's pre-existing regimen may include one of the following boosted ARV agents: ritonavir boosted lopinavir (LPV/r), atazanavir (ATV) + ritonavir (RTV), ATV + cobicistat (COBI) or ATV/COBI FDC, darunavir (DRV) + RTV, DRV+COBI or DRV/COBI FDC; or, one of the following unboosted ARV agents: efavirenz (EFV), rilpivirine (RPV), raltegravir (RAL), dolutegravir (DTG), maraviroc (MVC), or nevirapine (NVP).
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the FDA-Defined Snapshot Algorithm
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 48
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Determined by the FDA-Defined Snapshot Algorithm
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 96
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the FDA-Defined Snapshot Algorithm
The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 48
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 96 as Determined by the FDA-Defined Snapshot Algorithm
The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 96
Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 48 as Determined by the FDA-Defined Snapshot Algorithm
The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 48
Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 96 as Determined by the FDA-Defined Snapshot Algorithm
The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 96
Change From Baseline in CD4 Cell Count at Week 48
Time frame: Baseline; Week 48
Change From Baseline in CD4 Cell Count at Week 96
Time frame: Baseline; Week 96
Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48
Time frame: Baseline; Week 48
Percent Change From Baseline in Hip BMD at Week 96
Time frame: Baseline; Week 96
Percent Change From Baseline in Spine BMD at Week 48
Time frame: Baseline; Week 48
Percent Change From Baseline in Spine BMD at Week 96
Time frame: Baseline; Week 96
Participants were enrolled at study sites in North America and Europe. The first participant was screened on 29 June 2015. The last study visit occurred on 13 March 2019.
| Milestone | F/TAF | ABC/3TC |
|---|---|---|
| Started | 285 | 282 |
| Completed | 218 | 226 |
| Not completed | 67 | 56 |
| Withdrew: Randomized and never treated | 5 | 6 |
| Withdrew: Adverse event | 12 | 9 |
| Withdrew: Death | 2 | 0 |
| Withdrew: Lack of efficacy | 2 | 1 |
| Withdrew: Investigator's discretion | 8 | 8 |
| Withdrew: Non-compliance with study drug | 3 | 1 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Withdrew consent | 25 | 25 |
| Withdrew: Lost to follow-up | 9 | 5 |
| Milestone | F/TAF | ABC/3TC |
|---|---|---|
| Started | 6 | 5 |
| Completed | 6 | 5 |
| Not completed | 0 | 0 |
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | F/TAF | ABC/3TC |
|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the FDA-Defined Snapshot Algorithm | 88.6 | 92.4 |
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | F/TAF | ABC/3TC |
|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Determined by the FDA-Defined Snapshot Algorithm | 82.1 | 88.4 |
The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | F/TAF | ABC/3TC |
|---|---|---|
| Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the FDA-Defined Snapshot Algorithm | 1.8 | 0.7 |
The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | F/TAF | ABC/3TC |
|---|---|---|
| Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 96 as Determined by the FDA-Defined Snapshot Algorithm | 2.5 | 1.1 |
The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | F/TAF | ABC/3TC |
|---|---|---|
| Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 48 as Determined by the FDA-Defined Snapshot Algorithm | 85.7 | 87.3 |
The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | F/TAF | ABC/3TC |
|---|---|---|
| Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 96 as Determined by the FDA-Defined Snapshot Algorithm | 80.4 | 86.2 |
| cells/µL | F/TAF | ABC/3TC |
|---|---|---|
| Change From Baseline in CD4 Cell Count at Week 48 | -30 ± 152.3 | 2 ± 171.2 |
| cells/μL | F/TAF | ABC/3TC |
|---|---|---|
| Change From Baseline in CD4 Cell Count at Week 96 | -29 ± 160.7 | 10 ± 178.2 |
| percent change | F/TAF | ABC/3TC |
|---|---|---|
| Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48 | 0.246 ± 2.2914 | 0.086 ± 2.3315 |
| percent change | F/TAF | ABC/3TC |
|---|---|---|
| Percent Change From Baseline in Hip BMD at Week 96 | 0.169 ± 2.7277 | 0.021 ± 2.7212 |
| percent change | F/TAF | ABC/3TC |
|---|---|---|
| Percent Change From Baseline in Spine BMD at Week 48 | 0.081 ± 3.0051 | -0.052 ± 3.7550 |
| percent change | F/TAF | ABC/3TC |
|---|---|---|
| Percent Change From Baseline in Spine BMD at Week 96 | 0.178 ± 3.8881 | 0.235 ± 4.3066 |
Collected over First dose date to last dose date (maximum duration: 168 weeks) plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| F/TAF (Double-Blind Phase) | 5/280 (1.8%) | 55/280 (19.6%) | 190/280 (67.9%) |
| ABC/3TC (Double-Blind Phase) | 0/276 (0%) | 32/276 (11.6%) | 199/276 (72.1%) |
| Open-Label F/TAF From F/TAF | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Open-Label F/TAF From ABC/3TC | 0/5 (0%) | 0/5 (0%) | 2/5 (40%) |
| Event | F/TAF (Double-Blind Phase) | ABC/3TC (Double-Blind Phase) | Open-Label F/TAF From F/TAF | Open-Label F/TAF From ABC/3TC |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 5/280 | 2/276 | 0/6 | 0/5 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/280 | 3/276 | 0/6 | 0/5 |
| Deep vein thrombosisVascular disorders | 2/280 | 3/276 | 0/6 | 0/5 |
| Acute kidney injuryRenal and urinary disorders | 3/280 | 0/276 | 0/6 | 0/5 |
| GastroenteritisInfections and infestations | 0/280 | 2/276 | 0/6 | 0/5 |
| UrosepsisInfections and infestations | 1/280 | 2/276 | 0/6 | 0/5 |
| Chest painGeneral disorders | 2/280 | 0/276 | 0/6 | 0/5 |
| Type 2 diabetes mellitusMetabolism and nutrition disorders | 2/280 | 0/276 | 0/6 | 0/5 |
| Hodgkin's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/280 | 0/276 | 0/6 | 0/5 |
| Suicide attemptPsychiatric disorders | 2/280 | 1/276 | 0/6 | 0/5 |
| Event | F/TAF (Double-Blind Phase) | ABC/3TC (Double-Blind Phase) | Open-Label F/TAF From F/TAF | Open-Label F/TAF From ABC/3TC |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 57/280 | 49/276 | 0/6 | 1/5 |
| RhinitisInfections and infestations | 7/280 | 6/276 | 0/6 | 1/5 |
| Renal colicRenal and urinary disorders | 1/280 | 0/276 | 0/6 | 1/5 |
| Upper respiratory tract infectionInfections and infestations | 36/280 | 46/276 | 0/6 | 0/5 |
| Spinal painMusculoskeletal and connective tissue disorders | 0/280 | 1/276 | 1/6 | 0/5 |
| DiarrhoeaGastrointestinal disorders | 30/280 | 37/276 | 0/6 | 0/5 |
| CoughRespiratory, thoracic and mediastinal disorders | 34/280 | 30/276 | 0/6 | 0/5 |
| Back painMusculoskeletal and connective tissue disorders | 24/280 | 31/276 | 0/6 | 0/5 |
| HeadacheNervous system disorders | 31/280 | 25/276 | 0/6 | 0/5 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 28/280 | 29/276 | 0/6 | 0/5 |
The Safety Analysis Set included all randomized participants who received at least one dose of study drug. Participants were grouped according to the treatment they actually received.
| Age, Continuous(years) | F/TAF | ABC/3TC | Total |
|---|---|---|---|
| Mean | 51 ± 9.4 | 51 ± 9.3 | 51 ± 9.3 |
| Sex: Female, Male(Participants) | F/TAF | ABC/3TC | Total |
|---|---|---|---|
| Female | 40 | 61 | 101 |
| Male | 240 | 215 | 455 |
| Ethnicity (NIH/OMB)(Participants) | F/TAF | ABC/3TC | Total |
|---|---|---|---|
| Hispanic or Latino | 16 | 19 | 35 |
| Not Hispanic or Latino | 264 | 257 | 521 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | F/TAF | ABC/3TC | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 5 | 5 | 10 |
| Black | 64 | 66 | 130 |
| White | 205 | 199 | 404 |
| Other | 5 | 6 | 11 |
| Region of Enrollment(Participants) | F/TAF | ABC/3TC | Total |
|---|---|---|---|
| Belgium | 4 | 6 | 10 |
| Canada | 9 | 8 | 17 |
| Denmark | 4 | 3 | 7 |
| France | 18 | 17 | 35 |
| Germany | 20 | 19 | 39 |
| Ireland | 9 | 8 | 17 |
| Italy | 26 | 17 | 43 |
| Spain | 32 | 34 | 66 |
| Sweden | 3 | 4 | 7 |
| United Kingdom | 50 | 59 | 109 |
| United States | 105 | 101 | 206 |
| HIV-1 RNA Category(Participants) | F/TAF | ABC/3TC | Total |
|---|---|---|---|
| < 50 copies/mL | 278 | 273 | 551 |
| ≥ 50 copies/mL | 2 | 3 | 5 |
| CD4 Cell Count(cells/µL) | F/TAF | ABC/3TC | Total |
|---|---|---|---|
| Mean | 703 ± 298.7 | 727 ± 275.2 | 715 ± 287.3 |
| CD4 Cell Count Category(Participants) | F/TAF | ABC/3TC | Total |
|---|---|---|---|
| < 50 cells/µL | 0 | 1 | 1 |
| ≥ 50 to < 200 cells/µL | 0 | 0 | 0 |
| ≥ 200 to < 350 cells/µL | 20 | 16 | 36 |
| ≥ 350 to < 500 cells/µL | 56 | 38 | 94 |
| ≥ 500 cells/µL | 204 | 221 | 425 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
Ran from Jun 2015 to primary completion in Dec 2017, 29 months.
Results were first posted in Jun 2018, 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Emtricitabine · Tenofovir alafenamide